Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 5/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 3/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878901 | 0.90 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3LSSABL1 | |
| SCHEMBL5878713 | 0.89 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3ABL1 | |
| SCHEMBL6151597 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3SCN9ALSS | |
| SCHEMBL5878919 | 0.80 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3SCN9A | |
| SCHEMBL6151985 | 0.78 | SLC6A4 (0.84) | SLC6A4SLC6A2SLC6A3SCN9ALSS | |
| SCHEMBL5530111 | 0.71 | OPRM1 (0.56) | SLC6A4SLC6A2SLC6A3ABL1BCR | |
| SCHEMBL6159785 | 0.69 | CCNC (0.41) | SLC6A4SLC6A2SCN9ACCNCCDK8 | |
| SCHEMBL28562862 | 0.69 | SMN1; SMN2 (0.53) | CCNCCDK8MAPK8MAPK10 | |
| SCHEMBL21628389 | 0.69 | CHEK2 (0.45) | — | |
| SCHEMBL6151453 | 0.69 | SLC6A4 (0.84) | SLC6A4SLC6A2SLC6A3LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129234-B2 | Phenyl heterocyclyl ethers | PFIZER INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1377550-B9 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2005-11-23 | — | — | EP | disclosed |
| EP-1377550-B1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-20040106594-A1 | Phenyl heterocyclyl ethers | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| US-20030207857-A1 | Phenyl heterocyclyl ethers | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207857-A1 | Phenyl heterocyclyl ethers | CYP2E1, CYP1A1, CCNI | SLC6A4 3835/4885SLC6A2 4120/4885SLC6A3 3857/4885 |
| US-20040106594-A1 | Phenyl heterocyclyl ethers | CYP2E1, CYP1A1, CCNI | SLC6A4 3835/4885SLC6A2 4120/4885SLC6A3 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.